Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference
September 07 2016 - 6:00AM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, announces
that Mr Glyn Edwards, Chief Executive Officer, will present at the
18th Annual Rodman & Renshaw Global Investment Conference, 13
September 2016 at 2:35pm EDT in New York City.
A live audio webcast of the presentation will be
available through the Investors section on the Company’s website,
www.summitplc.com. A replay of the webcast will be available soon
after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit
Therapeutics Glyn Edwards / Richard Pye
(UK office)Erik Ostrowski / Michelle Avery (US office) |
|
Tel: +44 (0)1235
443 951 +1 617 225 4455 |
Cairn Financial
Advisers LLP (Nominated Adviser)Liam Murray / Tony
Rawlinson |
|
Tel: +44 (0)20 7148
7900 |
N+1
Singer (Broker)Aubrey Powell / Jen Boorer
|
|
Tel: +44 (0)20 7496
3000 |
MacDougall
Biomedical Communications(US media contact)Chris Erdman /
Karen Sharma |
|
Tel: +1 781 235 3060
cerdman@macbiocom.com ksharma@macbiocom.com |
Consilium
Strategic Communications (Financial public relations,
UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey
Neville |
|
Tel: +44 (0)20 3709
5700summit@consilium-comms.com |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024